350 related articles for article (PubMed ID: 35078279)
1. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Zeng X; Jiang Z; Duan J
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
[TBL] [Abstract][Full Text] [Related]
2. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
3. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
Dudek AZ; Wang X; Gu L; Duong S; Stinchcombe TE; Kratzke R; Borghaei H; Vokes EE; Kindler HL
Clin Lung Cancer; 2020 Nov; 21(6):553-561.e1. PubMed ID: 32727707
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
Jing XQ; Zhou L; Sun XD; Yu JM; Meng X
Medicine (Baltimore); 2016 Apr; 95(14):e3351. PubMed ID: 27057918
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
[TBL] [Abstract][Full Text] [Related]
9. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
Wahba NI; Khorshid O; Abo Elkasem F; Bahnassy A; Gaafer R
Asian Pac J Cancer Prev; 2023 Jan; 24(1):195-205. PubMed ID: 36708568
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
[TBL] [Abstract][Full Text] [Related]
11. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
Nagata Y; Sawada R; Takashima A; Shoji H; Honma Y; Iwasa S; Amano K; Kato K; Hamaguchi T; Shimada Y; Saruta M; Boku N
Jpn J Clin Oncol; 2019 Dec; 49(11):1004-1008. PubMed ID: 31287877
[TBL] [Abstract][Full Text] [Related]
13. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
15. Systemic treatment in patients with malignant pleural mesothelioma - real life experience.
Ziółkowska B; Cybulska-Stopa B; Papantoniou D; Suwiński R
BMC Cancer; 2022 Apr; 22(1):432. PubMed ID: 35443624
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.
Nakano T; Kuribayashi K; Kondo M; Morise M; Tada Y; Hirano K; Hayashi M; Tanaka M; Hirabayashi M
Asia Pac J Clin Oncol; 2021 Jun; 17(3):264-272. PubMed ID: 32893992
[TBL] [Abstract][Full Text] [Related]
18. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
Scagliotti GV; Gaafar R; Nowak AK; Nakano T; van Meerbeeck J; Popat S; Vogelzang NJ; Grosso F; Aboelhassan R; Jakopovic M; Ceresoli GL; Taylor P; Orlandi F; Fennell DA; Novello S; Scherpereel A; Kuribayashi K; Cedres S; Sørensen JB; Pavlakis N; Reck M; Velema D; von Wangenheim U; Kim M; Barrueco J; Tsao AS
Lancet Respir Med; 2019 Jul; 7(7):569-580. PubMed ID: 31103412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
